

**BEFORE THE
BOARD OF PHARMACY
DEPARTMENT OF CONSUMER AFFAIRS
STATE OF CALIFORNIA**

In the Matter of the Accusation Against:

**GLOVE WORK, INC., DBA CORBIN PHARMACY,
SCOTT KATZ, CHIEF EXECUTIVE OFFICER, 100% SHAREHOLDER,
DIRECTOR, SECRETARY AND CHIEF FINANCIAL OFFICER
Pharmacy Permit No. PHY 55733,**

**JANE HYUN HONG
Registered Pharmacist License No. RPH 70481,**

and

**MEHRNAZ AKHAVAN
Registered Pharmacist License No. RPH 40805**

Respondents.

Agency Case No. 7076

OAH No. 2022020052

DECISION AND ORDER

The attached Stipulated Settlement and Disciplinary Order is hereby adopted by the Board of Pharmacy, Department of Consumer Affairs, as its Decision in this matter.

This Decision shall become effective at 5:00 p.m. on August 30, 2023.

It is so ORDERED on July 31, 2023.

BOARD OF PHARMACY
DEPARTMENT OF CONSUMER AFFAIRS
STATE OF CALIFORNIA

By

A handwritten signature in black ink, appearing to read "Seung W. Oh". The signature is fluid and cursive, with the first name "Seung" and last name "Oh" clearly visible.

Seung W. Oh, Pharm.D.
Board President

1 ROB BONTA
Attorney General of California
2 SHAWN P. COOK
Supervising Deputy Attorney General
3 VINODHINI RAMAGOPAL
Deputy Attorney General
4 State Bar No. 240534
300 So. Spring Street, Suite 1702
5 Los Angeles, CA 90013
Telephone: (213) 269-6270
6 Facsimile: (916) 731-2126
Attorneys for Complainant
7

8 **BEFORE THE**
9 **BOARD OF PHARMACY**
10 **DEPARTMENT OF CONSUMER AFFAIRS**
11 **STATE OF CALIFORNIA**

12 In the Matter of the Accusation Against:

Case No. 7076

13 **GLOVE WORK, INC., DBA CORBIN**
14 **PHARMACY**
15 **19664 Ventura Blvd.**
Tarzana, CA 91356

OAH No. 2022020052

STIPULATED SETTLEMENT AND
DISCIPLINARY ORDER AS TO
MEHRNAZ AKHAVAN ONLY

16 **SCOTT KATZ, Chief Executive Officer,**
17 **100% Shareholder, Director, Secretary and**
Chief Financial Officer

18 **Pharmacy Permit No. PHY 55733,**

19 **JANE HYUN HONG**
20 **4143 Via Dolce #221**
21 **Marina Del Rey, CA 90292**

22 **Registered Pharmacist License No. RPH**
70481

23 **And**

24 **MEHRNAZ AKHAVAN**
25 **10600 Holman Ave., Apt. 1**
Los Angeles, CA 90024

26 **Registered Pharmacist License No. RPH**
27 **40805**

28 Respondents.

1 IT IS HEREBY STIPULATED AND AGREED by and between the parties to the above-
2 entitled proceedings that the following matters are true:

3 **PARTIES**

4 1. Anne Sodergren (Complainant) is the Executive Officer of the Board of Pharmacy
5 (Board). She brought this action solely in her official capacity and is represented in this matter by
6 Rob Bonta, Attorney General of the State of California, by Vinodhini Ramagopal, Deputy
7 Attorney General.

8 2. Respondent Mehrnaz Akhavan (Respondent) is represented in this proceeding by
9 attorney Herbert L. Weinberg, Esq., whose address is: 1990 South Bundy Drive, Suite 777, Los
10 Angeles, CA 90025.

11 3. On or about March 19, 1987, the Board of Pharmacy issued Registered Pharmacist
12 License Number RPH 40805 to Respondent. The Registered Pharmacist License was in full force
13 and effect at all times relevant to the charges brought herein and will expire on March 31, 2023,
14 unless renewed.

15 **JURISDICTION**

16 4. Accusation No. 7076 was filed before the Board, and is currently pending against
17 Respondent. The Accusation and all other statutorily required documents were properly served
18 on Respondent on November 12, 2021. Respondent timely filed its Notice of Defense contesting
19 the Accusation.

20 5. A copy of Accusation No. 7076 is attached as exhibit A and incorporated herein by
21 reference.

22 **ADVISEMENT AND WAIVERS**

23 6. Respondent has carefully read, fully discussed with counsel, and understands the
24 charges and allegations in Accusation No. 7076. Respondent has also carefully read, fully
25 discussed with counsel, and understands the effects of this Stipulated Settlement and Disciplinary
26 Order.

27 7. Respondent is fully aware of its legal rights in this matter, including the right to a
28 hearing on the charges and allegations in the Accusation; the right to confront and cross-examine

1 the witnesses against them; the right to present evidence and to testify on its own behalf; the right
2 to the issuance of subpoenas to compel the attendance of witnesses and the production of
3 documents; the right to reconsideration and court review of an adverse decision; and all other
4 rights accorded by the California Administrative Procedure Act and other applicable laws.

5 8. Respondent voluntarily, knowingly, and intelligently waives and gives up each and
6 every right set forth above.

7 **CULPABILITY**

8 9. Respondent understands and agrees that the charges and allegations in Accusation
9 No. 7076, if proven at a hearing, constitute cause for imposing discipline upon her Pharmacist
10 License.

11 10. For the purpose of resolving the Accusation without the expense and uncertainty of
12 further proceedings, Respondent agrees that, at a hearing, Complainant could establish a factual
13 basis for the charges in the Accusation, and that Respondent hereby gives up its right to contest
14 those charges.

15 11. Respondent agrees that her Pharmacist License is subject to discipline and she agrees
16 to be bound by the Board's probationary terms as set forth in the Disciplinary Order below.

17 **CONTINGENCY**

18 12. This stipulation shall be subject to approval by the Board of Pharmacy. Respondent
19 understands and agrees that counsel for Complainant and the staff of the Board of Pharmacy may
20 communicate directly with the Board regarding this stipulation and settlement, without notice to
21 or participation by Respondent or its counsel. By signing the stipulation, Respondent understands
22 and agrees that they may not withdraw its agreement or seek to rescind the stipulation prior to the
23 time the Board considers and acts upon it. If the Board fails to adopt this stipulation as its
24 Decision and Order, the Stipulated Settlement and Disciplinary Order shall be of no force or
25 effect, except for this paragraph, it shall be inadmissible in any legal action between the parties,
26 and the Board shall not be disqualified from further action by having considered this matter.

27 ///

28 ///

13. The parties understand and agree that Portable Document Format (PDF) and facsimile copies of this Stipulated Settlement and Disciplinary Order, including PDF and facsimile signatures thereto, shall have the same force and effect as the originals.

14. This Stipulated Settlement and Disciplinary Order is intended by the parties to be an integrated writing representing the complete, final, and exclusive embodiment of their agreement. It supersedes any and all prior or contemporaneous agreements, understandings, discussions, negotiations, and commitments (written or oral). This Stipulated Settlement and Disciplinary Order may not be altered, amended, modified, supplemented, or otherwise changed except by a writing executed by an authorized representative of each of the parties.

15. In consideration of the foregoing admissions and stipulations, the parties agree that the Board may, without further notice or formal proceeding, issue and enter the following Disciplinary Order:

DISCIPLINARY ORDER

IT IS HEREBY ORDERED that Pharmacist License Number RPH 40805 issued to Respondent Mehrnaz Akhavan is revoked. However, the revocation is stayed and Respondent is placed on probation for four (4) years on the following terms and conditions:

1. Obey All Laws

Respondent shall obey all state and federal laws and regulations.

Respondent shall report any of the following occurrences to the board, in writing, within seventy- two (72) hours of such occurrence:

- an arrest or issuance of a criminal complaint for violation of any provision of the Pharmacy Law, state and federal food and drug laws, or state and federal controlled substances laws
- a plea of guilty, or nolo contendere, no contest, or similar, in any state or federal
- criminal proceeding to any criminal complaint, information or indictment
- a conviction of any crime
- the filing of a disciplinary pleading, issuance of a citation, or initiation of another administrative action filed by any state or federal agency which involves

respondent's license or which is related to the practice of pharmacy or the manufacturing, obtaining, handling, distributing, billing, or charging for any drug, device or controlled substance.

Failure to timely report such occurrence shall be considered a violation of probation.

2. Report to the Board

Respondent shall report to the board quarterly, on a schedule as directed by the board or its designee. The report shall be made either in person or in writing, as directed. Among other requirements, respondent shall state in each report under penalty of perjury whether there has been compliance with all the terms and conditions of probation.

Failure to submit timely reports in a form as directed shall be considered a violation of probation. Any period(s) of delinquency in submission of reports as directed may be added to the total period of probation. Moreover, if the final probation report is not made as directed, probation shall be automatically extended until such time as the final report is made and accepted by the board.

3. Interview with the Board

Upon receipt of reasonable prior notice, respondent shall appear in person for interviews with the board or its designee, at such intervals and locations as are determined by the board or its designee. Failure to appear for any scheduled interview without prior notification to board staff, or failure to appear for two (2) or more scheduled interviews with the board or its designee during the period of probation, shall be considered a violation of probation.

4. Cooperate with Board Staff

Respondent shall timely cooperate with the board's inspection program and with the board's monitoring and investigation of respondent's compliance with the terms and conditions of her probation, including but not limited to: timely responses to requests for information by board staff; timely compliance with directives from board staff regarding requirements of any term or condition of probation; and timely completion of documentation pertaining to a term or condition of probation. Failure to timely cooperate shall be considered a violation of probation.

///

1 **5. Continuing Education**

2 Respondent shall provide evidence of efforts to maintain skill and knowledge as a
3 pharmacist as directed by the board or its designee.

4 **6. Reporting of Employment and Notice to Employers**

5 During the period of probation, respondent shall notify all present and prospective
6 employers of the decision in case number 7076 and the terms, conditions and restrictions imposed
7 on respondent by the decision, as follows:

8 Within thirty (30) days of the effective date of this decision, and within ten (10) days of
9 undertaking any new employment, respondent shall report to the board in writing the name,
10 physical address, and mailing address of each of her employer(s), and the name(s) and telephone
11 number(s) of all of her direct supervisor(s), as well as any pharmacist(s)-in-charge, designated
12 representative(s)-in-charge, responsible manager, or other compliance supervisor(s) and the work
13 schedule, if known. Respondent shall also include the reason(s) for leaving the prior
14 employment. Respondent shall sign and return to the board a written consent authorizing the
15 board or its designee to communicate with all of respondent's employer(s) and supervisor(s), and
16 authorizing those employer(s) or supervisor(s) to communicate with the board or its designee,
17 concerning respondent's work status, performance, and monitoring. Failure to comply with the
18 requirements or deadlines of this condition shall be considered a violation of probation.

19 Within thirty (30) days of the effective date of this decision, and within fifteen (15) days of
20 respondent undertaking any new employment, respondent shall cause (a) her direct supervisor, (b)
21 her pharmacist-in-charge, designated representative-in-charge, responsible manager, or other
22 compliance supervisor, and (c) the owner or owner representative of her employer, to report to the
23 board in writing acknowledging that the listed individual(s) has/have read the decision in case
24 number 7076, and terms and conditions imposed thereby. If one person serves in more than one
25 role described in (a), (b), or (c), the acknowledgment shall so state. It shall be the respondent's
26 responsibility to ensure that these acknowledgment(s) are timely submitted to the board. In the
27 event of a change in the person(s) serving the role(s) described in (a), (b), or (c) during the term
28 of probation, respondent shall cause the person(s) taking over the role(s) to report to the board in

1 writing within fifteen (15) days of the change acknowledging that he or she has read the decision
2 in case number 7076, and the terms and conditions imposed thereby.

3 If respondent works for or is employed by or through an employment service, respondent
4 must notify the person(s) described in (a), (b), and (c) above at every entity licensed by the board
5 of the decision in case number 7076, and the terms and conditions imposed thereby in advance of
6 respondent commencing work at such licensed entity. A record of this notification must be
7 provided to the board upon request.

8 Furthermore, within thirty (30) days of the effective date of this decision, and within fifteen
9 (15) days of respondent undertaking any new employment by or through an employment service,
10 respondent shall cause the person(s) described in (a), (b), and (c) above at the employment service
11 to report to the board in writing acknowledging that he or she has read the decision in case
12 number, and the terms and conditions imposed thereby. It shall be respondent's responsibility to
13 ensure that these acknowledgment(s) are timely submitted to the board.

14 Failure to timely notify present or prospective employer(s) or failure to cause the identified
15 person(s) with that/those employer(s) to submit timely written acknowledgments to the board
16 shall be considered a violation of probation.

17 "Employment" within the meaning of this provision includes any full-time, part-time,
18 temporary, relief, or employment/management service position as a Pharmacist, or any position
19 for which a Pharmacist is a requirement or criterion for employment, whether the respondent is an
20 employee, independent contractor or volunteer.

21 **7. Notification of Change(s) in Name, Address(es), or Phone Number(s)**

22 Respondent shall further notify the board in writing within ten (10) days of any change in
23 name, residence address, mailing address, e-mail address or phone number.

24 Failure to timely notify the board of any change in employer, name, address, or phone
25 number shall be considered a violation of probation.

26 **8. Restrictions on Supervision and Oversight of Licensed Facilities –**

27 During the period of probation, respondent shall not supervise any intern pharmacist, be the
28 pharmacist-in-charge, designated representative-in-charge, responsible manager or other

1 compliance supervisor of any entity licensed by the board, nor serve as a consultant. Assumption
2 of any such unauthorized supervision responsibilities shall be considered a violation of probation.

3 **9. Reimbursement of Board Costs**

4 As a condition precedent to successful completion of probation, respondent shall pay to the
5 board its costs of investigation and prosecution in the amount of \$20,000.00. Respondent shall
6 make said payments as follows:

7 There shall be no deviation from this schedule absent prior written approval by the board or
8 its designee. Failure to pay costs by the deadline(s) as directed shall be considered a violation of
9 probation.

10 Respondent shall be permitted to pay these costs in a payment plan approved by the board
11 or its designee, so long as full payment is completed no later than one (1) year prior to the end
12 date of probation.

13 **10. Probation Monitoring Costs**

14 Respondent shall pay any costs associated with probation monitoring as determined by the
15 board each and every year of probation. Such costs shall be payable to the board on a schedule as
16 directed by the board or its designee. Failure to pay such costs by the deadline(s) as directed shall
17 be considered a violation of probation.

18 **11. Status of License**

19 Respondent shall, at all times while on probation, maintain an active, current Pharmacist
20 License with the board, including any period during which suspension or probation is tolled.
21 Failure to maintain an active, current Pharmacist License shall be considered a violation of
22 probation.

23 If respondent's Pharmacist License expires or is cancelled by operation of law or otherwise
24 at any time during the period of probation, including any extensions thereof due to tolling or
25 otherwise, upon renewal or reapplication respondent's license shall be subject to all terms and
26 conditions of this probation not previously satisfied.

27 ///

28 ///

1 **12. License Surrender While on Probation**

2 Following the effective date of this decision, should respondent cease practice due to
3 retirement or health, or be otherwise unable to satisfy the terms and conditions of probation,
4 respondent may relinquish her Pharmacist License, including any indicia of licensure issued by
5 the board, along with a request to surrender the license. The board or its designee shall have the
6 discretion whether to accept the surrender or take any other action it deems appropriate and
7 reasonable. Upon formal acceptance of the surrender of the license, respondent will no longer be
8 subject to the terms and conditions of probation. This surrender constitutes a record of discipline
9 and shall become a part of the respondent's license history with the board.

10 Upon acceptance of the surrender, respondent shall relinquish Pharmacist License pocket
11 and/or wall license, including any indicia of licensure not previously provided to the board within
12 ten (10) days of notification by the board that the surrender is accepted if not already provided.
13 Respondent may not reapply for any license from the board for three (3) years from the effective
14 date of the surrender. Respondent shall meet all requirements applicable to the license sought as
15 of the date the application for that license is submitted to the board, including any outstanding
16 costs.

17 **13. Practice Requirement – Extension of Probation**

18 Except during periods of suspension, respondent shall, at all times while on probation, be
19 employed as a Pharmacist in California for a minimum of eighty (80) hours per calendar month.
20 Any month during which this minimum is not met shall extend the period of probation by one
21 month. During any such period of insufficient employment, respondent must nonetheless comply
22 with all terms and conditions of probation, unless respondent receives a waiver in writing from
23 the board or its designee.

24 If respondent does not practice as a Pharmacist in California for the minimum number of
25 hours in any calendar month, for any reason (including vacation), respondent shall notify the
26 board in writing within ten (10) days of the conclusion of that calendar month. This notification
27 shall include at least: the date(s), location(s), and hours of last practice; the reason(s) for the
28 interruption or reduction in practice; and the anticipated date(s) on which respondent will resume

1 practice at the required level. Respondent shall further notify the board in writing within ten (10)
2 days following the next calendar month during which respondent practices as a Pharmacist in
3 California for the minimum of hours. Any failure to timely provide such notification(s) shall be
4 considered a violation of probation.

5 It is a violation of probation for respondent's probation to be extended pursuant to the
6 provisions of this condition for a total period, counting consecutive and non-consecutive months,
7 exceeding thirty-six (36) months. The board or its designee may post a notice of the extended
8 probation period on its website.

9 **14. Violation of Probation**

10 If respondent has not complied with any term or condition of probation, the board shall
11 have continuing jurisdiction over respondent, and the board shall provide notice to respondent
12 that probation shall automatically be extended, until all terms and conditions have been satisfied
13 or the board has taken other action as deemed appropriate to treat the failure to comply as a
14 violation of probation, to terminate probation, and to impose the penalty that was stayed. The
15 board or its designee may post a notice of the extended probation period on its website.

16 If respondent violates probation in any respect, the board, after giving respondent notice
17 and an opportunity to be heard, may revoke probation and carry out the disciplinary order that
18 was stayed. If a petition to revoke probation or an accusation is filed against respondent during
19 probation, or the preparation of an accusation or petition to revoke probation is requested from
20 the Office of the Attorney General, the board shall have continuing jurisdiction and the period of
21 probation shall be automatically extended until the petition to revoke probation or accusation is
22 heard and decided, and the charges and allegations in Accusation No. 7076 shall be deemed true
23 and correct.

24 **15. Completion of Probation**

25 Upon written notice by the board or its designee indicating successful completion of
26 probation, respondent's license will be fully restored.

27 ///

28 ///

16. **Remedial Education**

Within ninety (90) days of the effective date of this decision, respondent shall submit to the board or its designee, for prior approval, an appropriate program of remedial education related to the grounds for discipline. The program of remedial education shall consist of at least six (6) hours per year at respondent's own expense. Fifty percent (50%) of the remedial education hours must be in-person or live webinar. All remedial education shall be in addition to, and shall not be credited toward, continuing education (CE) courses used for license renewal purposes for pharmacists. Additionally, respondent must complete Board training during the first year of probation.

Failure to timely submit for approval or complete the approved remedial education shall be considered a violation of probation. The period of probation will be automatically extended until such remedial education is successfully completed and written proof, in a form acceptable to the board, is provided to the board or its designee.

Following the completion of each course, the board or its designee may require the respondent, at her own expense, to take an approved examination to test the respondent's knowledge of the course. If the respondent does not achieve a passing score on the examination that course shall not count towards satisfaction of this term. Respondent shall take another course approved by the board in the same subject area.

17. **Ethics Course**

Within sixty (60) calendar days of the effective date of this decision, respondent shall enroll in a course in ethics, at respondent's expense, approved in advance by the board or its designee that complies with Title 16 California Code of Regulations section 1773.5. Respondent shall provide proof of enrollment upon request. Within five (5) days of completion, respondent shall submit a copy of the certificate of completion to the board or its designee. Failure to timely enroll in an approved ethics course, to initiate the course during the first year of probation, to successfully complete it before the end of the second year of probation, or to timely submit proof of completion to the board or its designee, shall be considered a violation of probation.

1 **18. Supervised Practice**

2 Within thirty (30) days of the effective date of this decision, respondent shall submit to the
3 board or its designee, for prior approval, the name of a Pharmacist by and not on probation with
4 the board, to serve as respondent's practice supervisor. Respondent will be required to have
5 supervised practice for the first two (2) years of probation only. As part of the documentation
6 submitted, respondent shall cause the proposed practice supervisor to report to the board in
7 writing acknowledging that he or she has read the decision in case number 7076, and is familiar
8 with the terms and conditions imposed thereby, including the level of supervision required by the
9 board or its designee. This level will be determined by the board or its designee, will be
10 communicated to the respondent on or before the effective date of this decision and shall be one
11 of the following:

12 Continuous – At least 75% of a work week

13 Substantial - At least 50% of a work week

14 Partial - At least 25% of a work week

15 Daily Review - Supervisor's review of probationer's daily activities within 24 hours

16 Respondent may practice only under the required level of supervision by an approved
17 practice supervisor. If, for any reason, including change of employment, respondent is no longer
18 supervised at the required level by an approved practice supervisor, within ten (10) days of this
19 change in supervision respondent shall submit to the board or its designee, for prior approval, the
20 name of a Pharmacist by and not on probation with the board, to serve as respondent's
21 replacement practice supervisor. As part of the documentation submitted, respondent shall cause
22 the proposed replacement practice supervisor to report to the board in writing acknowledging that
23 he or she has read the decision in case number 7076, and is familiar with the terms and conditions
24 imposed thereby, including the level of supervision required.

25 Any of the following shall result in the automatic suspension of practice by a respondent
26 and shall be considered a violation of probation:

27 ///

28 ///

1 Failure to nominate an initial practice supervisor, and to have that practice supervisor report
2 to the board in writing acknowledging the decision, terms and conditions, and supervision level,
3 within thirty (30) days;

4 Failure to nominate a replacement practice supervisor, and to have that practice supervisor
5 report to the board in writing acknowledging the decision, terms and conditions, and supervision
6 level, within ten (10) days;

7 Practicing in the absence of an approved practice supervisor beyond the initial or
8 replacement nomination period; or

9 Any failure to adhere to the required level of supervision.

10 Respondent shall not resume practice until notified in writing by the board or its designee.

11 During any suspension, respondent shall not enter any pharmacy area or any portion of the
12 licensed premises of a wholesaler, third-party logistics provider, veterinary food-animal drug
13 retailer or any other distributor of drugs which is licensed by the board, or any manufacturer, or
14 any area where dangerous drugs and/or dangerous devices or controlled substances are
15 maintained. Respondent shall not practice pharmacy nor do any act involving drug selection,
16 selection of stock, manufacturing, compounding, dispensing or patient consultation; nor shall
17 respondent manage, administer, or be a consultant to any licensee of the board, or have access to
18 or control the ordering, distributing, manufacturing or dispensing of dangerous drugs and/or
19 dangerous devices or controlled substances.

20 During any suspension, respondent shall not engage in any activity that requires the
21 professional judgment and/or licensure as a Pharmacist. Respondent shall not direct or control
22 any aspect of the practice of pharmacy or of the manufacture, distribution, wholesaling, or
23 retailing of dangerous drugs and/or dangerous devices or controlled substances.

24 Failure to comply with any suspension shall be considered a violation of probation.

25 **19. No Ownership or Management of Licensed Premises**

26 Respondent shall not own, have any legal or beneficial interest in, nor serve as a manager,
27 administrator, member, officer, director, trustee, associate, or partner of any business, firm,
28 partnership, or corporation currently or hereinafter licensed by the board. Respondent shall sell

1 or transfer any legal or beneficial interest in any entity licensed by the board within ninety (90)
2 days following the effective date of this decision and shall immediately thereafter provide written
3 proof thereof to the board. Failure to timely divest any legal or beneficial interest(s) or provide
4 documentation thereof shall be considered a violation of probation.

5 **ACCEPTANCE**

6 I have carefully read the above Stipulated Settlement and Disciplinary Order and have fully
7 discussed it with my attorney, Herbert L. Weinberg, Esq. I understand the stipulation and the
8 effect it will have on my Pharmacist License. I enter into this Stipulated Settlement and
9 Disciplinary Order voluntarily, knowingly, and intelligently, and agree to be bound by the
10 Decision and Order of the Board of Pharmacy.

11
12 DATED: _____

MEHRNAZ AKHAVAN
Respondent

14 I have read and fully discussed with Respondent Mehrnaz Akhavan the terms and
15 conditions and other matters contained in the above Stipulated Settlement and Disciplinary Order.
16 I approve its form and content.

17
18 DATED: _____

HERBERT L. WEINBERG, ESQ.
Attorney for Respondent

21 ///

1 or transfer any legal or beneficial interest in any entity licensed by the board within ninety (90)
2 days following the effective date of this decision and shall immediately thereafter provide written
3 proof thereof to the board. Failure to timely divest any legal or beneficial interest(s) or provide
4 documentation thereof shall be considered a violation of probation.

5 ACCEPTANCE

6 I have carefully read the above Stipulated Settlement and Disciplinary Order and have fully
7 discussed it with my attorney, Herbert L. Weinberg, Esq. I understand the stipulation and the
8 effect it will have on my Pharmacist License. I enter into this Stipulated Settlement and
9 Disciplinary Order voluntarily, knowingly, and intelligently, and agree to be bound by the
10 Decision and Order of the Board of Pharmacy.

11
12 DATED: 4/27/2023 Mehnaz Akhavan

13 MEHRNAZ AKHAVAN
Respondent

14 I have read and fully discussed with Respondent Mehrnaz Akhavan the terms and
15 conditions and other matters contained in the above Stipulated Settlement and Disciplinary Order.
16 I approve its form and content.

17
18 DATED: 4/27/2023 Herbert L. Weinberg, Esq.

19 HERBERT L. WEINBERG, ESQ.
20 Attorney for Respondent

21 ///

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

ENDORSEMENT

The foregoing Stipulated Settlement and Disciplinary Order is hereby respectfully submitted for consideration by the Board of Pharmacy.

DATED: _____

Respectfully submitted,

ROB BONTA
Attorney General of California
SHAWN P. COOK
Supervising Deputy Attorney General

VINODHINI RAMAGOPAL
Deputy Attorney General
Attorneys for Complainant

LA2020604104
65906510.docx


ENDORSEMENT

The foregoing Stipulated Settlement and Disciplinary Order is hereby respectfully submitted for consideration by the Board of Pharmacy.

DATED: April 27, 2023

Respectfully submitted,

ROB BONTA
Attorney General of California
SHAWN P. COOK
Supervising Deputy Attorney General



VINODHINI RAMAGOPAL
Deputy Attorney General
Attorneys for Complainant

LA2020604104
65906510.docx

Exhibit A

Accusation No. 7076

1 ROB BONTA
Attorney General of California
2 SHAWN P. COOK
Supervising Deputy Attorney General
3 VINODHINI RAMAGOPAL
Deputy Attorney General
4 State Bar No. 240534
300 So. Spring Street, Suite 1702
5 Los Angeles, CA 90013
Telephone: (213) 269-6270
6 Facsimile: (916) 731-2126
E-mail: Vinodhini.Ramagopal@doj.ca.gov
7 *Attorneys for Complainant*

8
9 **BEFORE THE**
BOARD OF PHARMACY
10 **DEPARTMENT OF CONSUMER AFFAIRS**
11 **STATE OF CALIFORNIA**

12 In the Matter of the Accusation Against:

Case No. 7076

13 **GLOVE WORK, INC., DBA CORBIN**
PHARMACY
14 **19664 Ventura Blvd.**
Tarzana, CA 91356

FIRST AMENDED ACCUSATION

15
16 **SCOTT KATZ, Chief Executive Officer,**
100% Shareholder, Director, Secretary and
17 **Chief Financial Officer**

18 **Pharmacy Permit No. PHY 55733,**

19 **JANE HYUN HONG**
20 **4143 Via Dolce #221**
Marina Del Rey, CA 90292

21 **Registered Pharmacist License No. RPH**
22 **70481**

23 **And**

24 **MEHRNAZ AKHAVAN**
25 **10600 Holman Ave., Apt. 1**
Los Angeles, CA 90024

26 **Registered Pharmacist License No. RPH**
27 **40805**

28 Respondents.

PARTIES

1. Anne Sodergren (Complainant) brings this Accusation solely in her official capacity as the Executive Officer of the Board of Pharmacy, Department of Consumer Affairs.

2. On or about August 29, 2017, the Board of Pharmacy issued Pharmacy Permit Number PHY 55733 to Glove Work, Inc., dba Corbin Pharmacy (Respondent Pharmacy). Respondent Scott Katz (Respondent Katz) is and has been the Chief Executive Officer, 100% Shareholder, Director, Secretary and Chief Financial Officer since August 29, 2017. Jane Hyun Hong was the Pharmacist-in-Charge from May 24, 2018 to December 3, 2021. The Pharmacy Permit was in full force and effect at all times relevant to the charges brought herein and expired on February 21, 2022.

3. On or about March 14, 2014, the Board of Pharmacy issued Registered Pharmacist License Number RPH 70481 to Respondent Jane Hyun Hong (Respondent Hong). The Registered Pharmacist License was in full force and effect at all times relevant to the charges brought herein and will expire on October 31, 2023, unless renewed.

4. On or about March 19, 1987, the Board of Pharmacy issued Registered Pharmacist License Number RPH 40805 to Respondent Mehrnaz Akhavan (Respondent Akhavan). The Registered Pharmacist License was in full force and effect at all times relevant to the charges brought herein and will expire on March 31, 2023, unless renewed.

JURISDICTION

5. This Accusation is brought before the Board of Pharmacy (Board), Department of Consumer Affairs, under the authority of the following laws. All section references are to the Business and Professions Code (Code) unless otherwise indicated.

6. Section 118, subdivision (b), of the Code provides that the suspension/expiration/surrender/cancellation of a license shall not deprive the Board/Registrar/Director of jurisdiction to proceed with a disciplinary action during the period within which the license may be renewed, restored, reissued or reinstated.

///

///

1 7. Section 4307 of the Code states:

2 (a) Any person who has been denied a license or whose license has been revoked or is
3 under suspension, or who has failed to renew his or her license while it was under suspension, or
4 who has been a manager, administrator, owner, member, officer, director, associate, partner, or
5 any other person with management or control of any partnership, corporation, trust, firm, or
6 association whose application for a license has been denied or revoked, is under suspension or has
7 been placed on probation, and while acting as the manager, administrator, owner, member,
8 officer, director, associate, partner, or any other person with management or control had
9 knowledge of or knowingly participated in any conduct for which the license was denied,
10 revoked, suspended, or placed on probation, shall be prohibited from serving as a manager,
11 administrator, owner, member, officer, director, associate, partner, or in any other position with
12 management or control of a licensee as follows:

13 (1) Where a probationary license is issued or where an existing license is placed on
14 probation, this prohibition shall remain in effect for a period not to exceed five years.

15 (2) Where the license is denied or revoked, the prohibition shall continue until the license is
16 issued or reinstated.

17 (b) “Manager, administrator, owner, member, officer, director, associate, partner, or any
18 other person with management or control of a license” as used in this section and Section 4308,
19 may refer to a pharmacist or to any other person who serves in such capacity in or for a licensee.

20 (c) The provisions of subdivision (a) may be alleged in any pleading filed pursuant to
21 Chapter 5 (commencing with Section 11500) of Part 1 of Division 3 of the Government Code.
22 However, no order may be issued in that case except as to a person who is named in the caption,
23 as to whom the pleading alleges the applicability of this section, and where the person has been
24 given notice of the proceeding as required by Chapter 5 (commencing with Section 11500) of Part
25 1 of Division 3 of the Government Code. The authority to proceed as provided by this subdivision
26 shall be in addition to the board's authority to proceed under Section 4339 or any other provision
27 of law.

28 ///

STATUTORY PROVISIONS

8. Section 4070 of the Code states in pertinent part:

(a) Except as provided in Section 4019 and subdivision (b), an oral or an electronic data transmission prescription as defined in subdivision (c) of Section 4040 shall as soon as practicable be reduced to writing by the pharmacist and shall be filled by, or under the direction of, the pharmacist. The pharmacist need not reduce to writing the address, telephone number, license classification, federal registry number of the prescriber or the address of the patient or patients if the information is readily retrievable in the pharmacy.

9. Section 4081, subdivision (a) of the Code states:

(a) All records of manufacture and of sale, acquisition, receipt, shipment, or disposition of dangerous drugs or dangerous devices shall be at all times during business hours open to inspection by authorized officers of the law, and shall be preserved for at least three years from the date of making. A current inventory shall be kept by every manufacturer, wholesaler, third-party logistics provider, pharmacy, veterinary food-animal drug retailer, outsourcing facility, physician, dentist, podiatrist, veterinarian, laboratory, licensed correctional clinic, as defined in Section 4187, clinic, hospital, institution, or establishment holding a currently valid and unrevoked certificate, license, permit, registration, or exemption under Division 2 (commencing with Section 1200) of the Health and Safety Code or under Part 4 (commencing with Section 16000) of Division 9 of the Welfare and Institutions Code who maintains a stock of dangerous drugs or dangerous devices.

10. Section 4113 of the Code states in relevant part:

(a) Every pharmacy shall designate a pharmacist-in-charge and, within 30 days thereof, shall notify the board in writing of the identity and license number of that pharmacist and the date he or she was designated.

(b) The proposed pharmacist-in-charge shall be subject to approval by the board. The board shall not issue or renew a pharmacy license without identification of an approved pharmacist-in-charge for the pharmacy.

///

1 (c) The pharmacist-in-charge shall be responsible for a pharmacy's compliance with all state
2 and federal laws and regulations pertaining to the practice of pharmacy.

3 (d) Every pharmacy shall notify the board in writing, on a form designed by the board,
4 within 30 days of the date when a pharmacist-in-charge ceases to act as the pharmacist-in-charge,
5 and shall on the same form propose another pharmacist to take over as the pharmacist-in-charge.
6 The proposed replacement pharmacist-in-charge shall be subject to approval by the board. If
7 disapproved, the pharmacy shall propose another replacement within 15 days of the date of
8 disapproval and shall continue to name proposed replacements until a pharmacist-in-charge is
9 approved by the board.

10 11. Section 4300 of the Code states:

11 (a) Every license issued may be suspended or revoked.

12 (b) The board shall discipline the holder of any license issued by the board,
13 whose default has been entered or whose case has been heard by the board and found
guilty, by any of the following methods:

14 (1) Suspending judgment.

15 (2) Placing him or her upon probation.

16 (3) Suspending his or her right to practice for a period not exceeding one year.

17 (4) Revoking his or her license.

18 (5) Taking any other action in relation to disciplining him or her as the board in
19 its discretion may deem proper.

20 (c) The board may refuse a license to any applicant guilty of unprofessional
conduct. The board may, in its sole discretion, issue a probationary license to any
21 applicant for a license who is guilty of unprofessional conduct and who has met all
other requirements for licensure. The board may issue the license subject to any
22 terms or conditions not contrary to public policy, including, but not limited to, the
following:

23 (1) Medical or psychiatric evaluation.

24 (2) Continuing medical or psychiatric treatment.

25 (3) Restriction of type or circumstances of practice.

26 (4) Continuing participation in a board-approved rehabilitation program.

27 (5) Abstention from the use of alcohol or drugs.

28 (6) Random fluid testing for alcohol or drugs.

(7) Compliance with laws and regulations governing the practice of pharmacy.

(d) The board may initiate disciplinary proceedings to revoke or suspend any probationary certificate of licensure for any violation of the terms and conditions of probation. Upon satisfactory completion of probation, the board shall convert the probationary certificate to a regular certificate, free of conditions.

(e) The proceedings under this article shall be conducted in accordance with Chapter 5 (commencing with Section 11500) of Part 1 of Division 3 of the Government Code, and the board shall have all the powers granted therein. The action shall be final, except that the propriety of the action is subject to review by the superior court pursuant to Section 1094.5 of the Code of Civil Procedure.

12. Section 4301 of the Code states:

The board shall take action against any holder of a license who is guilty of unprofessional conduct or whose license has been issued by mistake. Unprofessional conduct shall include, but is not limited to, any of the following:

(a) Procurement of a license by fraud or misrepresentation.

(b) Incompetence.

(c) Gross negligence.

(d) The clearly excessive furnishing of controlled substances in violation of subdivision (a) of Section 11153 of the Health and Safety Code.

(e) The clearly excessive furnishing of controlled substances in violation of subdivision (a) of Section 11153.5 of the Health and Safety Code. Factors to be considered in determining whether the furnishing of controlled substances is clearly excessive shall include, but not be limited to, the amount of controlled substances furnished, the previous ordering pattern of the customer (including size and frequency of orders), the type and size of the customer, and where and to whom the customer distributes its product.

(f) The commission of any act involving moral turpitude, dishonesty, fraud, deceit, or corruption, whether the act is committed in the course of relations as a licensee or otherwise, and whether the act is a felony or misdemeanor or not.

(g) Knowingly making or signing any certificate or other document that falsely represents the existence or nonexistence of a state of facts.

(h) The administering to oneself, of any controlled substance, or the use of any dangerous drug or of alcoholic beverages to the extent or in a manner as to be dangerous or injurious to oneself, to a person holding a license under this chapter, or to any other person or to the public, or to the extent that the use impairs the ability of the person to conduct with safety to the public the practice authorized by the license.

(i) Except as otherwise authorized by law, knowingly selling, furnishing, giving away, or administering, or offering to sell, furnish, give away, or administer, any controlled substance to an addict.

(j) The violation of any of the statutes of this state, of any other state, or of the United States regulating controlled substances and dangerous drugs.

1 (k) The conviction of more than one misdemeanor or any felony involving the
2 use, consumption, or self-administration of any dangerous drug or alcoholic beverage,
3 or any combination of those substances.

4 (l) The conviction of a crime substantially related to the qualifications,
5 functions, and duties of a licensee under this chapter. The record of conviction of a
6 violation of Chapter 13 (commencing with Section 801) of Title 21 of the United
7 States Code regulating controlled substances or of a violation of the statutes of this
8 state regulating controlled substances or dangerous drugs shall be conclusive
9 evidence of unprofessional conduct. In all other cases, the record of conviction shall
10 be conclusive evidence only of the fact that the conviction occurred. The board may
11 inquire into the circumstances surrounding the commission of the crime, in order to
12 fix the degree of discipline or, in the case of a conviction not involving controlled
13 substances or dangerous drugs, to determine if the conviction is of an offense
14 substantially related to the qualifications, functions, and duties of a licensee under this
15 chapter. A plea or verdict of guilty or a conviction following a plea of nolo
16 contendere is deemed to be a conviction within the meaning of this provision. The
17 board may take action when the time for appeal has elapsed, or the judgment of
18 conviction has been affirmed on appeal or when an order granting probation is made
19 suspending the imposition of sentence, irrespective of a subsequent order under
20 Section 1203.4 of the Penal Code allowing the person to withdraw his or her plea of
21 guilty and to enter a plea of not guilty, or setting aside the verdict of guilty, or
22 dismissing the accusation, information, or indictment.

23 (m) The cash compromise of a charge of violation of Chapter 13 (commencing
24 with Section 801) of Title 21 of the United States Code regulating controlled
25 substances or of Chapter 7 (commencing with Section 14000) of Part 3 of Division 9
26 of the Welfare and Institutions Code relating to the Medi-Cal program.

27 (n) The revocation, suspension, or other discipline by another state of a license
28 to practice pharmacy, operate a pharmacy, or do any other act for which a license is
required by this chapter that would be grounds for revocation, suspension, or other
discipline under this chapter. Any disciplinary action taken by the board pursuant to
this section shall be coterminous with action taken by another state, except that the
term of any discipline taken by the board may exceed that of another state, consistent
with the board's enforcement guidelines. The evidence of discipline by another state
is conclusive proof of unprofessional conduct.

(o) Violating or attempting to violate, directly or indirectly, or assisting in or
abetting the violation of or conspiring to violate any provision or term of this chapter
or of the applicable federal and state laws and regulations governing pharmacy,
including regulations established by the board or by any other state or federal
regulatory agency.

(p) Actions or conduct that would have warranted denial of a license.

(q) Engaging in any conduct that subverts or attempts to subvert an
investigation of the board.

(r) The selling, trading, transferring, or furnishing of drugs obtained pursuant to
Section 256b of Title 42 of the United States Code to any person a licensee knows or
reasonably should have known, not to be a patient of a covered entity, as defined in
paragraph (4) of subsection (a) of Section 256b of Title 42 of the United States Code.

(s) The clearly excessive furnishing of dangerous drugs by a wholesaler to a
pharmacy that primarily or solely dispenses prescription drugs to patients of long-

term care facilities. Factors to be considered in determining whether the furnishing of dangerous drugs is clearly excessive shall include, but not be limited to, the amount of dangerous drugs furnished to a pharmacy that primarily or solely dispenses prescription drugs to patients of long-term care facilities, the previous ordering pattern of the pharmacy, and the general patient population to whom the pharmacy distributes the dangerous drugs. That a wholesaler has established, and employs, a tracking system that complies with the requirements of subdivision (b) of Section 4164 shall be considered in determining whether there has been a violation of this subdivision. This provision shall not be interpreted to require a wholesaler to obtain personal medical information or be authorized to permit a wholesaler to have access to personal medical information except as otherwise authorized by Section 56 and following of the Civil Code. For purposes of this section, long-term care facility shall have the same meaning given the term in Section 1418 of the Health and Safety Code.

13. Section 4306.5 of the Code states:

Unprofessional conduct for a pharmacist may include any of the following:

(a) Acts or omissions that involve, in whole or in part, the inappropriate exercise of his or her education, training, or experience as a pharmacist, whether or not the act or omission arises in the course of the practice of pharmacy or the ownership, management, administration, or operation of a pharmacy or other entity licensed by the board.

(b) Acts or omissions that involve, in whole or in part, the failure to exercise or implement his or her best professional judgment or corresponding responsibility with regard to the dispensing or furnishing of controlled substances, dangerous drugs, or dangerous devices, or with regard to the provision of services.

(c) Acts or omissions that involve, in whole or in part, the failure to consult appropriate patient, prescription, and other records pertaining to the performance of any pharmacy function.

(d) Acts or omissions that involve, in whole or in part, the failure to fully maintain and retain appropriate patient-specific information pertaining to the performance of any pharmacy function.

14. Health and Safety Code section 11153 states in pertinent part:

(a) A prescription for a controlled substance shall only be issued for a legitimate medical purpose by an individual practitioner acting in the usual course of his or her professional practice. The responsibility for the proper prescribing and dispensing of controlled substances is upon the prescribing practitioner, but a corresponding responsibility rests with the pharmacist who fills the prescription. Except as authorized by this division, the following are not legal prescriptions: (1) an order purporting to be a prescription which is issued not in the usual course of professional treatment or in legitimate and authorized research; or (2) an order for an addict or habitual user of controlled substances, which is issued not in the course of professional treatment or as part of an authorized narcotic treatment program, for the purpose of providing the user with controlled substances, sufficient to keep him or her comfortable by maintaining customary use.

15. Health and Safety Code section 11167.5 states in pertinent part:

(a) An order for a controlled substance classified in Schedule II for a patient of a licensed skilled nursing facility, a licensed intermediate care facility, a licensed home health agency, or a licensed hospice may be dispensed upon an oral or electronically transmitted prescription. If the prescription is transmitted orally, the pharmacist shall, prior to filling the prescription, reduce the prescription to writing in ink in the handwriting of the pharmacist on a form developed by the pharmacy for this purpose. If the prescription is transmitted electronically, the pharmacist shall, prior to filling the prescription, produce, sign, and date a hard copy prescription. The prescriptions shall contain the date the prescription was orally or electronically transmitted by the prescriber, the name of the person for whom the prescription was authorized, the name and address of the licensed skilled nursing facility, licensed intermediate care facility, licensed home health agency, or licensed hospice in which that person is a patient, the name and quantity of the controlled substance prescribed, the directions for use, and the name, address, category of professional licensure, license number, and federal controlled substance registration number of the prescriber. The original shall be properly endorsed by the pharmacist with the pharmacy's state license number, the name and address of the pharmacy, and the signature of the person who received the controlled substances for the licensed skilled nursing facility, licensed intermediate care facility, licensed home health agency, or licensed hospice. A licensed skilled nursing facility, a licensed intermediate care facility, a licensed home health agency, or a licensed hospice shall forward to the dispensing pharmacist a copy of any signed telephone orders, chart orders, or related documentation substantiating each oral or electronically transmitted prescription transaction under this section.

REGULATORY PROVISIONS

16. California Code of Regulations, title 16, section 1714, subdivision (b) states:

(b) Each pharmacy licensed by the board shall maintain its facilities, space, fixtures, and equipment so that drugs are safely and properly prepared, maintained, secured and distributed. The pharmacy shall be of sufficient size and unobstructed area to accommodate the safe practice of pharmacy.

17. California Code of Regulations, title 16, section 1716, states:

Pharmacists shall not deviate from the requirements of a prescription except upon the prior consent of the prescriber or to select the drug product in accordance with Section 4073 of the Business and Professions Code.

Nothing in this regulation is intended to prohibit a pharmacist from exercising commonly-accepted pharmaceutical practice in the compounding or dispensing of a prescription.

18. California Code of Regulations, title 16, section 1717, states:

(a) No medication shall be dispensed on prescription except in a new container which conforms with standards established in the official compendia.

Notwithstanding the above, a pharmacist may dispense and refill a prescription for non-liquid oral products in a clean multiple-drug patient medication package (patient med pak), provided:

- 1 (1) a patient med pak is reused only for the same patient;
- 2 (2) no more than a one-month supply is dispensed at one time; and
- 3 (3) each patient med pak bears an auxiliary label which reads, store in a cool,
dry place.

4 (b) In addition to the requirements of Section 4040, Business and Professions
5 Code, the following information shall be maintained for each prescription on file and
shall be readily retrievable:

6 (1) The date dispensed, and the name or initials of the dispensing pharmacist.
7 All prescriptions filled or refilled by an intern pharmacist must also be initialed by the
supervising pharmacist before they are dispensed.

8 (2) The brand name of the drug or device; or if a generic drug or device is
9 dispensed, the distributor's name which appears on the commercial package label;
and

10 (3) If a prescription for a drug or device is refilled, a record of each refill,
11 quantity dispensed, if different, and the initials or name of the dispensing pharmacist.

12 (4) A new prescription must be created if there is a change in the drug, strength,
prescriber or directions for use, unless a complete record of all such changes is
13 otherwise maintained.

14 (c) Promptly upon receipt of an orally transmitted prescription, the pharmacist
shall reduce it to writing, and initial it, and identify it as an orally transmitted
15 prescription. If the prescription is then dispensed by another pharmacist, the
dispensing pharmacist shall also initial the prescription to identify him or herself.

16 All orally transmitted prescriptions shall be received and transcribed by a
17 pharmacist prior to compounding, filling, dispensing, or furnishing.

18 Chart orders as defined in Section 4019 of the Business and Professions Code
are not subject to the provisions of this subsection.

19 (d) A pharmacist may furnish a drug or device pursuant to a written or oral
20 order from a prescriber licensed in a State other than California in accordance with
Business and Professions Code Section 4005.

21 (e) A pharmacist may transfer a prescription for Schedule III, IV, or V
22 controlled substances to another pharmacy for refill purposes in accordance with Title
21, Code of Federal Regulations, section 1306.26.

23 Prescriptions for other dangerous drugs which are not controlled substances
24 may also be transferred by direct communication between pharmacists or by the
receiving pharmacist's access to prescriptions or electronic files that have been
25 created or verified by a pharmacist at the transferring pharmacy. The receiving
pharmacist shall create a written prescription; identifying it as a transferred
26 prescription; and record the date of transfer and the original prescription number.
When a prescription transfer is accomplished via direct access by the receiving
27 pharmacist, the receiving pharmacist shall notify the transferring pharmacy of the
transfer. A pharmacist at the transferring pharmacy shall then assure that there is a
28 record of the prescription as having been transferred, and the date of transfer. Each
pharmacy shall maintain inventory accountability and pharmacist accountability and

dispense in accordance with the provisions of section 1716 of this Division.
Information maintained by each pharmacy shall at least include:

- (1) Identification of pharmacist(s) transferring information;
 - (2) Name and identification code or address of the pharmacy from which the prescription was received or to which the prescription was transferred, as appropriate;
 - (3) Original date and last dispensing date;
 - (4) Number of refills and date originally authorized;
 - (5) Number of refills remaining but not dispensed;
 - (6) Number of refills transferred.
- (f) The pharmacy must have written procedures that identify each individual pharmacist responsible for the filling of a prescription and a corresponding entry of information into an automated data processing system, or a manual record system, and the pharmacist shall create in his/her handwriting or through hand-initializing a record of such filling, not later than the beginning of the pharmacy's next operating day. Such record shall be maintained for at least three years.

19. California Code of Regulations, title 16, section 1718, states in relevant part:

"Current Inventory" as used in Sections 4081 and 4332 of the Business and Professions Code shall be considered to include complete accountability for all dangerous drugs handled by every licensee enumerated in Sections 4081 and 4332.

20. California Code of Regulations, title 16, section 1761, states:

- (a) No pharmacist shall compound or dispense any prescription which contains any significant error, omission, irregularity, uncertainty, ambiguity or alteration. Upon receipt of any such prescription, the pharmacist shall contact the prescriber to obtain the information needed to validate the prescription.
- (b) Even after conferring with the prescriber, a pharmacist shall not compound or dispense a controlled substance prescription where the pharmacist knows or has objective reason to know that said prescription was not issued for a legitimate medical purpose.

COST RECOVERY

21. Section 125.3 of the Code provides, in pertinent part, that the Board may request the administrative law judge to direct a licensee found to have committed a violation or violations of the licensing act to pay a sum not to exceed the reasonable costs of the investigation and enforcement of the case, with failure of the licensee to comply subjecting the license to not being renewed or reinstated. If a case settles, recovery of investigation and enforcement costs may be included in a stipulated settlement.

DRUG CLASSIFICATIONS

BRAND NAME	GENERIC NAME	DANGEROUS DRUG PER B&P 4022	CONTROLLED SUBSTANCE PER H&S	INDICATIONS FOR USE
Norco/Lortab	Hydrocodone/acetaminophen (APAP)	Yes	Yes-Schedule II per H&S 11055(b)(1)(I)(ii) Yes-Scheduled II per Title CFR 1308.12	Pain
Percolone/Roxicodone	Oxycodone	Yes	Yes-Scheduled II per H&S 11055(b)(1)(M)	Pain
Phenergan with Codeine Syrup	Promethazine/codeine syrup	Yes	Yes-Scheduled V per H&S 11058(c)(1)	Cough
Eliquis	Apixaban	Yes	No	Blood clots/stroke
Pepcid	Famotidine	Yes	No	Acid Reflux
Ozempic	Semaglutide	Yes	No	Diabetes
Pennsaid	Diclofenac Sodium	Yes	No	Topical non-steroidal anti-inflammatory
Farxiga	Dapagliflozin	Yes	No	Diabetes
Vascepa	Icosapent ethyl	Yes	No	High Triglycerides
Zegerid	Omeprazole/Bicarbonate	Yes	No	Heartburn
Restasis	Cyclosporine	Yes	No	Dry Eye
Fluocinonide-E	Fluocinonide	Yes	No	Topical Steroid for Itch

FACTUAL ALLEGATIONS

22. At all times relevant herein, Scott Katz was the Chief Executive Officer, 100% Shareholder, Director, Secretary and Chief Financial Officer of Respondent Pharmacy – a

community pharmacy located in the city of Tarzana, CA. Respondent Hong was the Pharmacist-in-Charge of Respondent Pharmacy from May 24, 2018 to December 3, 2021. Respondent Akhavan was employed as a pharmacist with Respondent Pharmacy.

23. The Board performed a CURES¹ review and found that numerous controlled substance prescriptions were dispensed by Respondent Pharmacy. Said prescriptions were known to have patterns of red flags of abuse and illegitimacy.

24. The Board's investigation involved reviewing Respondent Pharmacy records and original prescription documents from August 29, 2017 through June 16, 2020. This review found a number of prescriptions having been dispensed with deviations from the prescribers' orders.

MEDICATION ERRORS

25. 2/23/2018 PRESCRIPTION ISSUED TO PATIENT KC

A. Patient KC was written a prescription for oxycodone 10/325 mg. Instead, Respondent Pharmacy dispensed oxycodone 30 mg. Additionally, on February 12, 2018 Respondent Pharmacy dispensed Patient KC 120 tablets of oxycodone 30 mg with directions to take one table every six hours, which would have been a 30-day supply. There was no documentation to justify dispensing another 90 tablets before the previous supply would have been exhausted. In response to the Board's investigation, Respondent Hong indicated that Patient KC was in hospice and the prescription was faxed in to be filled and the hard copy was received within 72 hours and that the pharmacist working at the time called the providers but did not transfer the information to the hard copy. Respondent Akhavan's responses to this investigation did not address the deviation from the prescriber's orders.

///

///

¹ CURES is an acronym for "California Utilization Review and Evaluation System." It contains over 100 million entries of controlled substance drugs that were dispensed in California. Pharmacists and prescribers can register with the Department of Justice to obtain access to the CURES data through the California Prescription Drug Monitoring Program (PDMP). Patient Activity Reports (PARs) are provided and reflect all controlled substances dispensed to an individual. CURES herein refers to CURES in general and PARs. Pharmacies are required to report to the California Department of Justice every schedule II, II and IV drug prescription under Health and Safety Code section 11165, subdivision (d).

1 26. 7/17/2019 PRESCRIPTION ISSUED TO PATIENT SF

2 A. Patient SF was written a prescription for 120 tablets of oxycodone 30 mg to be
3 taken every six hours. The notation on the prescription shows the prescriber approved the
4 prescription to be changed to 240 tablets of oxycodone 15 mg. Respondent Pharmacy records
5 indicate that 240 tablets of oxycodone 15 mg were dispensed, directing 1 tablet every 6 hours.
6 Patient SF's dose was not lowered since the prescription was processed as a 30-day supply.
7 There was no notation on the prescription document of prior prescriber consent to deviate from
8 the directions prescribed. Respondent Akhavan's responses to this investigation did not address
9 the deviation from the prescriber's orders.

10 27. 9/24/2019 PRESCRIPTION ISSUED TO PATIENT AK

11 A. Patient AK was written a prescription for 3 and ½ tablets daily of oxycodone 30
12 mg. Respondent Pharmacy records indicate that the dispensing directions provided were for 1 ½
13 tablets daily. Previously, Patient AK has been dispensed the same medication to be taken four
14 times per day. There was no notation on the prescription document of prior prescriber consent to
15 deviate from the directions prescribed or to clarify the unusual dosing prescribed. Respondent
16 Akhavan's responses to this investigation did not address the deviation from the prescriber's
17 orders.

18 28. 12/6/2019 PRESCRIPTION ISSUED TO PATIENT LJ

19 A. Patient LJ was written a prescription for oxycodone 30 mg with directions for 1
20 tablet 4 times per day. Respondent Pharmacy records indicate directions dispensed as 1 tablet
21 twice per day. In response to this investigation, Respondents Hong and Akhavan indicated there
22 was a verbal order phone in by the prescriber and that the original prescription provided
23 directions to be take twice daily.

24 29. 1/16/2020 PRESCRIPTION ISSUED TO PATIENT SY

25 A. Patient SY was written a prescription for oxycodone 30 mg with directions for
26 1 tablet every 6 hours. Respondent Pharmacy dispensed directions for 1 tablet every 8 hours.
27 There was no notation on the prescription document of prior prescriber consent to deviate from
28 the directions prescribed. In response to this investigation, Respondent Hong stated this

1 prescription was mistyped. Respondent Akhavan's responses to this investigation did not address
2 the deviation from the prescriber's orders.

3 30. 2/6/2020 PRESCRIPTION ISSUED TO PATIENT LJ

4 A. Patient LJ was written a prescription for oxycodone 30 mg with directions for 1
5 tablet 3 times per day. Respondent Pharmacy dispensed directions for 1 tablet twice per day.
6 There was no notation on the prescription document of prior prescriber consent to deviate from
7 the directions prescribed. In response to this investigation, Respondent Hong stated that this was
8 a hospice patient for which the prescriber transmitted an oral prescription, which differed from
9 the written prescription. Respondent Akhavan's responses to this investigation did not address the
10 deviation from the prescriber's orders.

11 31. 2/13/2020 PRESCRIPTION ISSUED TO PATIENT FH

12 A. Patient FH was written a prescription for Oxycontin 30 mg but Respondent
13 Pharmacy dispensed oxycodone 30 mg. There was no notation on the prescription document of
14 prior prescriber consent to deviate from the drug prescribed. In response to this investigation,
15 Respondents Hong and Akhavan provided a letter from the prescriber that stated the prescription
16 should have been written for oxycodone instead of Oxycontin. Prior prescriber consent of the
17 change of drug was not documented before dispensing nor did Respondent Pharmacy records
18 identify the dispensing pharmacist.

19 32. 3/12/2020 PRESCRIPTION ISSUED TO PATIENT AA

20 A. Patient AA was written a prescription for oxycodone 30 mg with directions for
21 1 tablet 3 times per day. Respondent Pharmacy dispensed oxycodone 30 mg with inaccurate
22 directions for 1 tablet 4 times per day. There was no notation on the prescription document of
23 prior prescriber consent to deviate from the directions prescribed. In response to this
24 investigation, Respondent Hong stated that this was a hospice patient for which the prescriber
25 transmitted an oral prescription, which differed from the written prescription. Respondent
26 Akhavan's responses to this investigation did not address the deviation from the prescriber's
27 orders.

28 ///

1 33. 3/12/2020 PRESCRIPTION ISSUED TO PATIENT FN

2 A. Patient FN was written a prescription for oxycodone 30 mg with directions for
3 1 tablet 3 times per day. Respondent Pharmacy dispensed oxycodone 30 mg with inaccurate
4 directions for 1 tablet twice per day. There was no notation on the prescription document of prior
5 prescriber consent to deviate from the directions prescribed. In response to this investigation,
6 Respondent Hong stated that this was a hospice patient for which the prescriber transmitted an
7 oral prescription, which differed from the written prescription. Respondent Akhavan's responses
8 to this investigation did not address the deviation from the prescriber's orders.

9 34. 3/20/2020 PRESCRIPTION ISSUED TO PATIENT BC

10 A. Patient BC was written a prescription for oxycodone 15 mg with directions for
11 4 tablets 4 times per day. Respondent Pharmacy dispensed oxycodone 15 mg with inaccurate
12 directions for 1 tablet 3 times per day. Previously, this patient had been dispensed the same
13 medication to be taken as one tablet (15 mg) 3 times per day. There was no notation on the
14 prescription document of prior consent to deviate from the directions prescribed or to clarify the
15 unusual dosage change. Respondent Akhavan's responses to this investigation did not address the
16 deviation from the prescriber's orders.

17 **CORRESPONDING RESPONSIBILITY**

18 35. The Board's Inspector reviewed Respondent Pharmacy's dispensing data regarding
19 both controlled and non-controlled prescriptions, a total of 117,745 prescriptions. The Board's
20 Inspector found Respondent Pharmacy found oxycodone 30 mg to be in the top dozen most
21 common drugs dispensed. The Board's Inspector reviewed Respondent Pharmacy's prescription
22 records and determined the percentage of cash payments for controlled substances was over two
23 to three times than non-controlled substances. In response, Respondent Hong stated that some
24 insurances do not cover controlled substances and that the above issue could in part be due to
25 billing a partial of the prescriptions as insurance and part as cash.

26 36. Regarding oxycodone prescriptions, the Board's Inspector found that Respondent
27 Pharmacy dispensed 1,130 prescriptions of oxycodone 30 mg, a higher percentage (83.1%)
28 compared to other lower strengths of oxycodone (5 mg, 10 mg, 15 mg, and 20 mg).

1 37. The Board's Inspector reviewed the top ten prescribers who wrote prescriptions for
2 oxycodone 30 mg and who accounted for the majority of oxycodone 30 mg prescriptions
3 dispensed by Respondent Pharmacy. Of the top ten prescribers, the Board's Inspector evaluated
4 patterns of prescribing for four of them.

5 38. Pejman Shirazi, MD (Dr. Shirazi) is licensed by the California Medical Board as a
6 physician and surgeon. Respondent Pharmacy's prescription documents revealed that oxycodone
7 30 mg was the most common controlled substance prescribed by Dr. Shirazi and dispensed by
8 Respondent Pharmacy. The Board's Inspector further found that almost 95% of said oxycodone
9 prescriptions were for the highest strength available, uniformity of treatment for multiple patients
10 receiving similar or identical controlled substances, at times receiving identical or similar
11 prescriptions on the same days, and at least nine patients not tolerant to opioids started, or
12 restarted, on high oxycodone doses.

13 39. John Korzelius, MD (Dr. Korzelius) is licensed by the California Medical Board as a
14 physician and surgeon. On August 5, 2020, the U.S. Department of Justice announced the arrest
15 of Dr. Korzelius alleging his involvement in a narcotics trafficking ring that sold illegal opioid
16 prescriptions for cash through a series of sham medical clinics. The Board's Inspector reviewed
17 dispensing records provided by Respondent Pharmacy, which revealed 50 controlled substances
18 dispensed pursuant to prescriptions from Dr. Korzelius. Of said 50 prescriptions, 96% were for
19 cash and for oxycodone 30 mg. The Board's Inspector further found that almost 92% of
20 oxycodone prescriptions were for the highest strength, uniformity of treatment for multiple
21 patients receiving similar or identical controlled substances, at times receiving identical or similar
22 prescriptions on the same days, and at least eleven patients not tolerant to opioids started, or
23 restarted, on high oxycodone doses.

24 40. Jennifer M. Edwards, PA (PA Edwards) was licensed by the California Physician
25 Assistant Board as a physician assistant. PA Edwards surrendered her Physician Assistant license
26 with the Physician Assistant Board effective 08/23/2022 following a felony conviction after
27 pleading guilty to one count of conspiracy to distribute and to possess with intent to distribute
28 oxycodone on or about 06/01/2021. The Board's Inspector reviewed dispensing records and

1 prescription documents provided by Respondent Pharmacy. Regarding controlled substances
2 dispensed, per prescriptions from PA Edwards, the Board's Inspector found high cash payment
3 percentage for controlled substances, promethazine/codeine was the most common controlled
4 substance dispensed, uniformity of treatment for some patients receiving similar or identical
5 controlled substances, and at least three patients not tolerant to opioids started, or restarted, on
6 high oxycodone doses.

7 41. Fariba Javaherian, MD (Dr. Javaherian) is licensed by the California Medical Board
8 as a physician and surgeon. The Board's Inspector reviewed dispensing records and prescription
9 documents provided by Respondent Pharmacy. Dr. Javaherian's primary areas of practice are
10 listed as dermatology and internal medicine. The top controlled substance and most common
11 drug, prescribed by Dr. Javaherian and dispensed by Respondent Pharmacy was oxycodone 30
12 mg. Regarding controlled substances dispensed, per prescriptions from Dr. Javaherian, the
13 Board's Inspector found that almost all oxycodone prescriptions were for the highest strength
14 available, uniformity of treatment for multiple patients receiving similar or identical controlled
15 substances, sometimes receiving identical or similar prescriptions on the same days, very few
16 prescriptions for hydrocodone/APAP, which is one of the most common drugs dispensed in the
17 country and a common starting point for pain patients, and at least two patients not tolerant to
18 opioids started, or restarted, on high oxycodone doses.

19 **HIGH STARTING DOSES OF OXYCODONE**

20 42. The Board's Inspector reviewed original prescriptions and found 38 instances in
21 which Respondent Pharmacy dispensed oxycodone 30 mg to 35 different patients at dosages
22 which were at least twice the recommended dose and without any documentation of effective
23 intervention by a pharmacist.

24 **BOARD'S AUDIT FROM JANUARY 1, 2020 THROUGH JANUARY 24, 2022**

25 43. The Board received information from Prime Therapeutics indicating that Respondent
26 Pharmacy had submitted prescription claims indicative of fraud, waste, and abuse.

27 44. The Board conducted an audit of Respondent Pharmacy regarding seven dangerous
28 drugs from January 1, 2020 through January 24, 2022 based on information provided by

Respondent Pharmacy, Walgreens (Respondent Pharmacy had transferred all records to Walgreens after closing), and the drug wholesalers. The audit revealed the following:

- (a) An overage of 547 Farxiga 10mg tablets;
- (b) An overage of 11 Ozempic 1mg pens;
- (c) An overage of 580 Eliquis 2.5 mg tablets;
- (d) An overage of 881 Pennsaid 2% pump (112gm) bottles; and
- (e) An overage of 3,191 Famotidine 40mg/5ml syrup 50ml bottles.

An overage indicates that Respondent Corbin processed prescriptions for more drug than they had purchased.

45. It was unlikely that Respondent Pharmacy had these large quantities in stock given their purchasing history from wholesaler, Cardinal. Specifically:

(a) Farxiga 10mg tablet: Respondent Pharmacy purchased one to two bottles at a time each costing \$516.85 from Cardinal. An overage of 547 tablets would have been 18 bottles totaling \$9,303.30 in inventory;

(b) Ozempic 1mg pen: Respondent Pharmacy purchased one or two pens at a time each costing \$821.79 from Cardinal. An overage of 11 pens totaled \$9,039.69 in inventory;

(c) Eliquis 2.5mg tablet: Respondent Pharmacy purchased one or two bottles at a time each costing \$484.10 from Cardinal. An overage of 580 tablets would have been 9 bottles totaling \$4,356.90;

(d) Pennsaid 2% pump (112gm) bottles: Respondent Pharmacy purchased four bottles at a time each costing \$2,406.58 from Cardinal. An overage of 881 bottles totaled \$2,120,196.90 in inventory; and

(e) Famotidine 40mg/5ml syrup 50ml bottles: Respondent Pharmacy purchased between 20 and 70 bottles at a time each costing \$21.01 from Cardinal. An overage of 3,191 bottles totaled \$67,042.91 in inventory.

46. The Board's audit supported the information provided by Prime Therapeutics indicating that Respondent Pharmacy had dispensed more drug than they had purchased on five of the seven drugs audited.

47. During the course of its investigation, the Board learned that Respondent Pharmacy had filed a discontinuation of business on February 21, 2022, closed, and transferred all records to Walgreens. Also, Respondent Hong had left the company and ceased being the Pharmacist-In-Charge (“PIC”) on December 3, 2021. Respondent Pharmacy did not have a designated PIC from December 3, 2021 to February 21, 2022.

THE BOARD’S INVESTIGATION (2022)

48. On or about June 21, 2022, the Board received information from Qlarant, a Medicare drug integrity contractor, related to possible fraud, waste, and abuse claims at Respondent Pharmacy. Qlarant had conducted audits on behalf of several insurance companies, including CVS Caremark and found that Respondent Pharmacy had failed to collect copayments for prescriptions, processed prescriptions with incorrect day supply causing prescription to be refilled too soon, and had medication shortages.

49. The Board received information from Qlarant based on the audits conducted. Specifically on or about January 27, 2020, CVS Caremark sent Respondent Pharmacy a list of the prescription discrepancies found from their initial prescription audit, which was conducted on October 15, 2017. CVS Caremark had found that twenty-three prescriptions refilled too soon and three prescriptions with insufficient directions. The Board confirmed the information provided by Qlarant based on the prescription documents provided by Respondent Pharmacy. For the prescriptions refilled too soon, the prescriptions were entered with the incorrect days’ supply considering the directions and package size. This caused future refills to be processed too soon. The prescriptions filled with insufficient direction for use were entered as “apply to affected area” without specifying the area size and amount needed. See Table A:

Table A: Prescription Discrepancies Found by CVS Caremark		
<i><u>Refill Too Soon</u></i>		
Prescription #	Date of Refill	Drug Name
605690	5/15/2018	Qvar Inh 80mcg
607917	6/12/2018	Lantus solo pen 100 u/ml
604577	7/11/2018	Symbicort Inh 160/4.5mcg

611369	9/6/2018	Symbicort Inh 160/4.5mcg
613664	9/28/2018	Symbicort Inh 160/4.5mcg
607688	8/2/2018	Symbicort Inh 160/4.5mcg
615388	11/1/2018	Symbicort Inh 160/4.5mcg
615902	12/28/2018	Symbicort Inh 160/4.5mcg
614910	11/16/2018	Symbicort Inh 160/4.5mcg
612369	10/3/2018	Symbicort Inh 160/4.5mcg
616803	11/29/2018	Symbicort Inh 160/4.5mcg
616792	11/27/2018	Symbicort Inh 160/4.5mcg
612497	10/9/2018 12/4/2018	Qvar inh 80mcg
619243	2/19/2019 4/22/2019	Symbicort Inh 160/4.5mcg
614910	1/15/2019	Symbicort Inh 160/4.5mcg
616792	2/4/2019 4/9/2019	Symbicort Inh 160/4.5mcg
617146	2/19/2019 4/9/2019	Qvar inh 80mcg
616638	2/19/2019	Qvar inh 80mcg
624300	4/23/2019	Qvar inh 80mcg
<u>Insufficient Directions for Use</u>		
619088	2/20/2019 3/18/2019 4/11/2019	Clobetasol oint 0.05%

50. Additionally, based on the information received from Qlarant, Respondent Pharmacy failed to provide proof of co-payment collections for twenty-three prescriptions. See Table B:

Table B: Co-Payment Not Collected		
Prescription #	Date of Refill	Drug Name
664618	2/5/2021	Doxepin 5% cream
664699	1/21/2021 2/19/2021	Omeprazole/Bicarbonate 40mg/1680mg
665009	11/2/2020	Lidoderm 5% patch
666003	9/14/202 1/7/2021	Famotidine 40mg/5ml suspension
668117	10/5/2020 2/8/2021	Famotidine 40mg/5ml suspension
668676	10/12/2020	Famotidine 40mg/5ml suspension
669747	10/22/2020	Famotidine 40mg/5ml suspension

670210	10/27/2020	Famotidine 40mg/5ml suspension
673306	1/8/2021	Famotidine 40mg/5ml suspension
674376	12/7/2020 12/22/2020	Famotidine 40mg/5ml suspension
674506	12/20/2020	Lidoderm 5% patch
676131	12/25/2020 1/26/2021 2/24/2021	Famotidine 40mg/5ml suspension
678494	1/22/2021 3/4/2021 4/5/2021	Famotidine 40mg/5ml suspension
678576	1/22/2021	Famotidine 40mg/5ml suspension
680487	2/12/2021	Famotidine 40mg/5ml suspension
682580	3/5/2021	Omeprazole/Bicarbonate 40mg/1680mg
683896	3/19/2021	Omeprazole/Bicarbonate 40mg/1680mg
684443	3/30/2021 4/24/2021	Omeprazole/Bicarbonate 40mg/1680mg
684502	3/25/2021 4/22/2021 5/24/2021	Famotidine 40mg/5ml suspension
684855	5/13/2021	Omeprazole/Bicarbonate 40mg/1680mg
686031	5/12/2021	Lidoderm 5% patch
689178	5/12/2021	Omeprazole/Bicarbonate 40mg/1680mg
689561	5/14/2021	Famotidine 40mg/5ml suspension

51. An audit of Respondent Pharmacy between May 1, 2020 and May 31, 2020, by CVS Caremark of 50 drugs, resulted in 20 drug shortages. Respondent Pharmacy was terminated from the CVC Caremark network when they discontinued business on February 14, 2022.

52. The Board conducted an audit of Respondent Pharmacy regarding from January 1, 2020 through January 24, 2022 based on information provided by Respondent Pharmacy, Walgreens (Respondent Pharmacy had transferred all records to Walgreens after closing), and the drug wholesalers. The audit resulted in overages of:

(a) An overage of 28,895 capsules of Vascepa 1gm;

1 (b) An overage of 26,400 grams of fluocinonide 0.1% cream;

2 (c) An overage of 16,260 vials of Restasis 0.4ml;

3 (d) An overage of 18 vials of Restasis 5.5ml multi-dose vials; and

4 (e) An overage of 10,470 packets of Omeprazole/Bicarbonate 40mg/1680mg.

5 An overage indicates that Respondent Corbin dispensed more drug than they had
6 purchased for each drug demonstrating insurance fraud.

7 53. Based on the purchase prices provided by the wholesaler, the total purchases not
8 made by Respondent Pharmacy for the drugs audited are:

9 (a) Vascepa 1gm: 120 capsules cost \$321.05. An overage of 28,895 capsules is
10 \$77,306.16 worth of inventory never purchased;

11 (b) Fluocinonide 0.1% cream: a 120gm tube cost \$21.01. An overage of 26,400 grams
12 is \$4,622.20 worth of inventory never purchased;

13 (c) Restasis 0.4ml vials: 60 vials cost \$593.37. An overage of 16,260 vials is
14 \$160,803.27 worth of inventory never purchased;

15 (d) Restasis 5.5ml multi-dose vials: One vial cost \$596.44. An overage of 18 vials is
16 \$10,735.92 of inventory never purchased; and

17 (e) Omeprazole/bicarbonate 40mg/1680mg packets: 30 packets cost \$359.91. An
18 overage of 10,470 packets is \$125,608.59 worth of inventory never purchased.

19 Respondent Pharmacy failed to purchase \$379,076.14 worth of inventory to cover
20 prescription claims for the five drugs audited.

21 **FIRST CAUSE FOR DISCIPLINE**

22 (Variation from Prescription)

23 54. Respondent Pharmacy is subject to disciplinary action pursuant to Code section 4301,
24 subdivision (j) and/or (o) in conjunction with California Code of Regulations section 1716, in
25 conjunction with Health and Safety Code section 11167.5, based on evidence reviewed by a
26 Board Inspector, Respondent dispensed prescriptions which deviated prescribers' orders and
27 failed to document verbal order prescriptions for hospice patients. The allegations of paragraphs
28 22 through 42 above are realleged as though fully set forth.

1 **SECOND CAUSE FOR DISCIPLINE**

2 (Unprofessional Conduct- Failed to Comply with Corresponding Responsibility Requirements)

3 55. Respondent Pharmacy is subject to discipline pursuant to Code section 4300 for
4 unprofessional conduct as defined in section 4301, subdivisions (d), (j), and (o), in conjunction
5 with Health and Safety Code section 11153(a) based on evidence reviewed by a Board Inspector,
6 Respondent failed to meet its corresponding responsibility to assure legitimate prescriptions, in
7 that Respondent ignored and/or failed to appropriately respond to numerous warning signs or red
8 flags that should put a reasonable and prudent dispensing pharmacist on notice that prescriptions
9 for patients may not have been legitimate. The allegations of paragraphs 22 through 42 above are
10 realleged as though fully set forth.

11 **THIRD CAUSE FOR DISCIPLINE**

12 (Variation from Prescription)

13 56. Respondent Hong is subject to disciplinary action pursuant to Code section 4301,
14 subdivision (j) and/or (o) in conjunction with California Code of Regulations section 1716, in
15 conjunction with Health and Safety Code section 11167.5, based on evidence reviewed by a
16 Board Inspector, Respondent dispensed prescriptions which deviated from prescribers' orders and
17 failed to document verbal order prescriptions for hospice patients. The allegations of paragraphs
18 22 through 42 above are realleged as though fully set forth.

19 **FOURTH CAUSE FOR DISCIPLINE**

20 (Unprofessional Conduct Failed to Comply with Corresponding Responsibility Requirements)

21 57. Respondent Hong is subject to discipline pursuant to Code section 4300 for
22 unprofessional conduct as defined in section 4301, subdivisions (d), (j), and (o), in conjunction
23 with Health and Safety Code section 11153(a) based on evidence reviewed by a Board Inspector,
24 Respondent failed to meet her corresponding responsibility to assure legitimate prescriptions, in
25 that Respondent ignored and/or failed to appropriately respond to numerous warning signs or red
26 flags that should put a reasonable and prudent dispensing pharmacist on notice that prescriptions
27 for patients may not have been legitimate. The allegations of paragraphs 22 through 42 above are
28 realleged as though fully set forth.

1 **FIFTH CAUSE FOR DISCIPLINE**

2 (Gross Negligence)

3 58. Respondent Hong is subject to disciplinary action under section 4300 for
4 unprofessional conduct as defined in section 4301, subdivision (c) in that Respondent Hong
5 committed gross negligence in her practice as a pharmacist, her acts and/or omissions which were
6 an extreme departure from the standard of care, which under similar circumstances, would have
7 been ordinarily exercised by a competent pharmacist. The allegations of paragraphs 22 through
8 42 above are realleged as though fully set forth.

9 **SIXTH CAUSE FOR DISCIPLINE**

10 (Unprofessional Conduct)

11 59. Respondent Hong is subject to discipline pursuant to Code section 4300 for
12 unprofessional conduct as defined in section 4301, and section 4306.5, in that Respondent's acts
13 or omissions involve, in whole or in part, the inappropriate exercise of his education, training, or
14 experience as a pharmacist, in that Respondent ignored and/or failed to appropriately respond to
15 numerous warning signs or red flags that should put a reasonable and prudent dispensing
16 pharmacist on notice that prescriptions for patients may not have been legitimate. The allegations
17 of paragraphs 22 through 42 above are realleged as though fully set forth.

18 **SEVENTH CAUSE FOR DISCIPLINE**

19 (Unprofessional Conduct Failed to Comply with Corresponding Responsibility Requirements)

20 60. Respondent Akhavan is subject to discipline pursuant to Code section 4300 for
21 unprofessional conduct as defined in section 4301, subdivisions (d), (j), and (o), in conjunction
22 with Health and Safety Code section 11153(a) based on evidence reviewed by a Board Inspector,
23 Respondent failed to meet her corresponding responsibility to assure legitimate prescriptions, in
24 that Respondent ignored and/or failed to appropriately respond to numerous warning signs or red
25 flags that should put a reasonable and prudent dispensing pharmacist on notice that prescriptions
26 for patients may not have been legitimate. The allegations of paragraphs 22 through 42 above are
27 realleged as though fully set forth.

28 ///

1 **EIGHTH CAUSE FOR DISCIPLINE**

2 (Failure to Timely Notify the Board of a New Pharmacist-In-Charge)

3 61. Respondent Pharmacy is subject to disciplinary action pursuant to Code section 4113,
4 subdivision (d) in that Respondent Pharmacy failed to report a new PIC to the Board within 30
5 days as required. Specifically, Respondent Hong ceased to act as the PIC on December 3, 2021
6 and Respondent Pharmacy did not designate a new PIC within 30 days. Respondent Pharmacy
7 filed a discontinuation of business on February 21, 2022 and failed to designated a PIC from
8 December 3, 2021 to February 21, 2022. The allegations of paragraphs 43 through 46 above are
9 realleged as though fully set forth.

10 **NINTH CAUSE FOR DISCIPLINE**

11 (Failure to Maintain Accountability of Dangerous Drugs)

12 62. Respondent Pharmacy is subject to disciplinary action pursuant to Code sections
13 4081, subdivision (a), section 4301, subdivision (j) and/or (o), in conjunction with California
14 Code of Regulations, title 16, section 1718 in that that Respondent Pharmacy failed to maintain
15 complete accountability of all dangerous drugs. Specifically, an audit of dangerous drugs from
16 January 1, 2020 through January 24, 2022 revealed overages of 547 Farxiga 10mg tablets, 11
17 Ozempic 1mg pens, 580 Eliquis 2.5mg tablets, 881 Pennsaid 2% pump (112gm) bottles, and
18 3,191 Famotidine 40mg/5ml 50ml bottles. These overages indicated Respondent Pharmacy had
19 processed prescriptions for more drug than they had purchased failing to purchase approximately
20 \$2,209,939.70 worth of inventory. The allegations of paragraphs 43 through 46 above are
21 realleged as though fully set forth.

22 **TENTH CAUSE FOR DISCIPLINE**

23 (Unprofessional Conduct: Failure to Maintain, Secure, and Distribute Dangerous Drugs)

24 63. Respondent Pharmacy is subject to disciplinary action pursuant to Code section 4301,
25 subdivision (j) and/or (o) in conjunction with California Code of Regulations, title 16, section
26 1714, subdivision (b) in that Respondent Pharmacy failed to properly maintain, secure, and
27 distribute dangerous drugs. Specifically, an audit of dangerous drugs from January 1, 2020
28 through January 24, 2022 revealed overages of 547 Farxiga 10mg tablets, 11 Ozempic 1mg pens,

1 580 Eliquis 2.5mg tablets, 881 Pennsaid 2% pump (112gm) bottles, and 3,191 Famotidine
2 40mg/5ml 50ml bottles. These overages indicated Respondent Pharmacy had processed
3 prescriptions for more drug than they had purchased failing to purchase approximately
4 \$2,209,939.70 worth of inventory. The allegations of paragraphs 43 through 46 above are
5 realleged as though fully set forth.

6 **ELEVENTH CAUSE FOR DISCIPLINE**

7 (Unprofessional Conduct: Dishonesty and Fraud)

8 64. Respondent Pharmacy is subject to disciplinary action pursuant to Code section 4301,
9 subdivision (f) for unprofessional conduct in that Respondent Pharmacy processed prescriptions
10 for more drug than they had purchased, which is indicative of dishonesty and fraud. Specifically,
11 an audit of dangerous drugs from January 1, 2020 through January 24, 2022 revealed overages of
12 547 Farxiga 10mg tablets, 11 Ozempic 1mg pens, 580 Eliquis 2.5mg tablets, 881 Pennsaid 2%
13 pump (112gm) bottles, and 3,191 Famotidine 40mg/5ml 50ml bottles. These overages indicated
14 Respondent Pharmacy had processed prescriptions for more drug than they had purchased failing
15 to purchase approximately \$2,209,939.70 worth of inventory. The allegations of paragraphs 43
16 through 46 above are realleged as though fully set forth.

17 **TWELFTH CAUSE FOR DISCIPLINE**

18 (Failure to Maintain Accountability of Dangerous Drugs)

19 65. Respondent Hong is subject to disciplinary action pursuant to Code sections 4081,
20 subdivision (a), section 4301, subdivision (j) and/or (o), and section 4113, subdivision (c) in
21 conjunction with California Code of Regulations, title 16, section 1718 in that Respondent Hong,
22 as the PIC of Respondent Pharmacy from May 24, 2018 to December 3, 2021, failed to maintain
23 complete accountability of all dangerous drugs. Specifically, an audit of dangerous drugs from
24 January 1, 2020 through January 24, 2022 revealed overages of 547 Farxiga 10mg tablets, 11
25 Ozempic 1mg pens, 580 Eliquis 2.5mg tablets, 881 Pennsaid 2% pump (112gm) bottles, and
26 3,191 Famotidine 40mg/5ml 50ml bottles. These overages indicated Respondent Pharmacy had
27 processed prescriptions for more drug than they had purchased and failed to purchase
28

1 approximately \$2,209,939.70 worth of inventory. The allegations of paragraphs 43 through 46
2 above are realleged as though fully set forth.

3 **THIRTEENTH CAUSE FOR DISCIPLINE**

4 (Unprofessional Conduct: Failure to Maintain, Secure, and Distribute Dangerous Drugs)

5 66. Respondent Hong is subject to disciplinary action pursuant to Code section 4301,
6 subdivision (j) and/or (o), and section 4113, subdivision (c) in conjunction with California Code
7 of Regulations, title 16, section 1714, subdivision (b) in that Respondent Hong, as the PIC of
8 Respondent Pharmacy from May 24, 2018 to December 3, 2021, failed to properly maintain,
9 secure, and distribute dangerous drugs. Specifically, an audit of dangerous drugs from January 1,
10 2020 through January 24, 2022 revealed overages of 547 Farxiga 10mg tablets, 11 Ozempic 1mg
11 pens, 580 Eliquis 2.5mg tablets, 881 Pennsaid 2% pump (112gm) bottles, and 3,191 Famotidine
12 40mg/5ml 50ml bottles. These overages indicated Respondent Pharmacy had processed
13 prescriptions for more drug than they had purchased failing to purchase approximately
14 \$2,209,939.70 worth of inventory. The allegations of paragraphs 43 through 46 above are
15 realleged as though fully set forth.

16 **FOURTEENTH CAUSE FOR DISCIPLINE**

17 (Unprofessional Conduct: Dishonesty and Fraud)

18 67. Respondent Hong is subject to disciplinary action pursuant to Code section 4301,
19 subdivision (f) and section 4113, subdivision (c) for unprofessional conduct in that Respondent
20 Hong, as the PIC of Respondent Pharmacy from May 24, 2018 to December 3, 2021, processed
21 prescriptions for more drug than they had purchased, which is indicative of dishonesty and fraud.
22 Specifically, an audit of dangerous drugs from January 1, 2020 through January 24, 2022 revealed
23 overages of 547 Farxiga 10mg tablets, 11 Ozempic 1mg pens, 580 Eliquis 2.5mg tablets, 881
24 Pennsaid 2% pump (112gm) bottles, and 3,191 Famotidine 40mg/5ml 50ml bottles. These
25 overages indicated Respondent Pharmacy had processed prescriptions for more drug than they
26 had purchased failing to purchase approximately \$2,209,939.70 worth of inventory. The
27 allegations of paragraphs 43 through 46 above are realleged as though fully set forth.

28 ///

1 **FIFTEENTH CAUSE FOR DISCIPLINE**

2 (Failure to Maintain Accountability and Records of Dangerous Drugs)

3 68. Respondent Pharmacy is subject to disciplinary action pursuant to Code sections
4 4081, subdivision (a), section 4301, subdivision (j) and/or (o), in conjunction with California
5 Code of Regulations, title 16, section 1718 in that that Respondent Pharmacy failed to maintain
6 complete accountability of all dangerous drugs. Specifically, an audit of dangerous drugs from
7 January 1, 2020 through January 24, 2022 revealed overages of 28,895 capsules of Vascepa 1gm;
8 26,400 grams of fluocinonide 0.1% cream; 16,260 vials of Restasis 0.4ml; 18 vials of Restasis
9 5.5ml multi-dose; and 10,470 packets of Omeprazole/Bicarbonate 40mg/1680mg. These overages
10 indicated Respondent Pharmacy had processed prescriptions for more drug than they had
11 purchased and failed to purchase approximately \$379,076.14 worth of inventory. The allegations
12 of paragraphs 48 through 53 above are realleged as though fully set forth.

13 **SIXTEENTH CAUSE FOR DISCIPLINE**

14 (Unprofessional Conduct: Failure to Maintain, Secure, and Distribute Dangerous Drugs)

15 69. Respondent Pharmacy is subject to disciplinary action pursuant to Code section 4301,
16 subdivision (j) and/or (o) in conjunction with California Code of Regulations, title 16, section
17 1714, subdivision (b) in that Respondent Pharmacy failed to distribute dangerous drugs.
18 Specifically, an audit of dangerous drugs from January 1, 2020 through January 24, 2022 revealed
19 overages of 28,895 capsules of Vascepa 1gm; 26,400 grams of fluocinonide 0.1% cream; 16,260
20 vials of Restasis 0.4ml; 18 vials of Restasis 5.5ml multi-dose; and 10,470 packets of
21 Omeprazole/Bicarbonate 40mg/1680mg. These overages indicated Respondent Pharmacy had
22 processed prescriptions for more drug than they had purchased and failed to purchase
23 approximately \$379,076.14 worth of inventory. The allegations of paragraphs 48 through 53
24 above are realleged as though fully set forth.

25 **SEVENTEENTH CAUSE FOR DISCIPLINE**

26 (Unprofessional Conduct: Dishonesty and Fraud)

27 70. Respondent Pharmacy is subject to disciplinary action pursuant to Code section 4301,
28 subdivision (f) for unprofessional conduct in that Respondent Pharmacy processed prescriptions

1 for more drug than they had purchased, which is indicative of dishonesty and fraud. Specifically,
2 an audit of dangerous drugs from January 1, 2020 through January 24, 2022 revealed overages of
3 28,895 capsules of Vascepa 1gm; 26,400 grams of fluocinonide 0.1% cream; 16,260 vials of
4 Restasis 0.4ml; 18 vials of Restasis 5.5ml multi-dose; and 10,470 packets of
5 Omeprazole/Bicarbonate 40mg/1680mg. These overages indicated Respondent Pharmacy had
6 processed prescriptions for more drug than they had purchased and failed to purchase
7 approximately \$379,076.14 worth of inventory. Additionally, Respondent Pharmacy incorrectly
8 processed prescriptions with the wrong day supply causing future refills to be too soon to fill and
9 insufficient directions for use as summarized in Table A, paragraph 47. Also, Respondent
10 Pharmacy failed to provide proof of copayment collection for prescriptions as summarized in
11 Table B, paragraph 48. The allegations of paragraphs 48 through 53 above are realleged as though
12 fully set forth.

13 **EIGHTEENTH CAUSE FOR DISCIPLINE**

14 (Failure to Maintain Accountability and Records of Dangerous Drugs)

15 71. Respondent Hong is subject to disciplinary action pursuant to Code sections 4081,
16 subdivision (a), section 4301, subdivision (j) and/or (o), and section 4113, subdivision (c) in
17 conjunction with California Code of Regulations, title 16, section 1718 in that Respondent Hong,
18 as the PIC of Respondent Pharmacy from May 24, 2018 to December 3, 2021, failed to maintain
19 complete accountability of all dangerous drugs. Specifically, an audit of dangerous drugs from
20 January 1, 2020 through January 24, 2022 revealed overages of 28,895 capsules of Vascepa 1gm;
21 26,400 grams of fluocinonide 0.1% cream; 16,260 vials of Restasis 0.4ml; 18 vials of Restasis
22 5.5ml multi-dose; and 10,470 packets of Omeprazole/Bicarbonate 40mg/1680mg. These overages
23 indicated Respondent Pharmacy had processed prescriptions for more drug than they had
24 purchased and failed to purchase approximately \$379,076.14 worth of inventory. The allegations
25 of paragraphs 48 through 53 above are realleged as though fully set forth.

26 ///

27 ///

28 ///

1 **NINETEENTH CAUSE FOR DISCIPLINE**

2 (Unprofessional Conduct: Failure to Maintain, Secure, and Distribute Dangerous Drugs)

3 72. Respondent Hong is subject to disciplinary action pursuant to Code section 4301,
4 subdivision (j) and/or (o), and section 4113, subdivision (c) in conjunction with California Code
5 of Regulations, title 16, section 1714, subdivision (b) in that Respondent Hong, as the PIC of
6 Respondent Pharmacy from May 24, 2018 to December 3, 2021, failed to properly distribute
7 dangerous drugs. Specifically, an audit of dangerous drugs from January 1, 2020 through January
8 24, 2022 revealed overages of 28,895 capsules of Vascepa 1gm; 26,400 grams of fluocinonide
9 0.1% cream; 16,260 vials of Restasis 0.4ml; 18 vials of Restasis 5.5ml multi-dose; and 10,470
10 packets of Omeprazole/Bicarbonate 40mg/1680mg. These overages indicated Respondent
11 Pharmacy had processed prescriptions for more drug than they had purchased and failed to
12 purchase approximately \$379,076.14 worth of inventory. The allegations of paragraphs 48
13 through 53 above are realleged as though fully set forth.

14 **TWENTIETH CAUSE FOR DISCIPLINE**

15 (Unprofessional Conduct: Dishonesty and Fraud)

16 73. Respondent Hong is subject to disciplinary action pursuant to Code section 4301,
17 subdivision (f) and section 4113, subdivision (c) for unprofessional conduct in that Respondent
18 Hong, as the PIC of Respondent Pharmacy from May 24, 2018 to December 3, 2021, failed to
19 collect prescription copayments, process prescriptions with the correct day supply and sufficient
20 directions, and processed prescriptions for more drug than they had purchased, which is indicative
21 of dishonesty and fraud. Specifically, an audit of dangerous drugs from January 1, 2020 through
22 January 24, 2022 revealed overages of 28,895 capsules of Vascepa 1gm; 26,400 grams of
23 fluocinonide 0.1% cream; 16,260 vials of Restasis 0.4ml; 18 vials of Restasis 5.5ml multi-dose;
24 and 10,470 packets of Omeprazole/Bicarbonate 40mg/1680mg. These overages indicated
25 Respondent Pharmacy had processed prescriptions for more drug than they had purchased and
26 failed to purchase approximately \$379,076.14 worth of inventory. Additionally, Respondent
27 Pharmacy incorrectly processed prescriptions with the wrong day supply causing future refills to
28 be too soon to fill and insufficient directions for use as summarized in Table A, paragraph 49.

Also, Respondent Pharmacy failed to provide proof of copayment collection for prescriptions as summarized in Table B, paragraph 50. The allegations of paragraphs 48 through 53 above are realleged as though fully set forth.

DISCIPLINARY CONSIDERATIONS

74. To determine the degree of penalty to be imposed on Respondent(s), if any, Complainant makes the following additional allegations:

A. Prior Citation (Respondent Akhavan) - On or about January 25, 2017, Administrative Citation/Assessment of Fine No. **CI 2016 73680** was issued to Respondent Akhavan for violating Codes and Regulations as set forth below. The citation is now final.

Code/Regulation(s) Violated	Offense
CA Code of Regulations (CCR), title 16, § 1714 subd. (d)	Operational Standards and Security; Pharmacist responsible for pharmacy security

B. Prior Citation (Respondent Akhavan) - On or about October 1, 2019, Administrative Citation/Assessment of Fine No. **CI 2018 84712** was issued to Respondent Akhavan for violating Codes and Regulations as set forth below, resulting in the issuance of a \$3,500.00 fine. The citation is now final.

Code/Regulation(s) Violated	Offense	Amount of Fine
Health & Safety Code § 11164 subd. (a)/Health & Safety Code § 11162.1 subd. (a)(2)(10)(13)/11162.1(b)	Each prescription for a controlled substance classified in Schedule II, III, IV, or V, except as authorized by subdivision (b), shall be made on a controlled substance prescription form as specified in Section 11162.1/Prescription forms for Controlled Substances; (2) A watermark "California Security Prescription" shall be printed on the backside of the prescription; (10) Check boxes shall be printed on the form so that the prescriber may indicate the number of refills ordered; (13) An identifying number assigned to the approved security printer by the Department of Justice/(b) Each batch of controlled substance prescription forms shall have the lot number printed on the form	\$2,000

Bus. & Prof. Code § 4081 subd. (a)/Bus. & Prof. Code § 4105 subd. (a) & (c)/ Bus. & Prof. Code § 4169 subd. (a)/Bus. & Prof. Code § 4333 subd. (a)	Records of Dangerous Drugs and Devices Kept Open for Inspection; Maintenance of Records, Current Inventory/Retaining Records of Dangerous Drugs and Devices on Licensed Premises; All records shall be retained on the licensed premises in a readily retrievable form/for a period of three years from the date of making/Prohibited Acts; Purchase, trade, sell, or transfer dangerous drugs to unlicensed person or entity.../Maintaining prescriptions on the premises for at least three years	\$500
CA Code of Regulations (CCR), title 16, § 1717 subd. (b)	Information shall be maintained for each prescription on file and readily retrievable	\$1,000

OTHER MATTERS

75. Section 4307 of the Code states:

(a) Any person who has been denied a license or whose license has been revoked or is under suspension, or who has failed to renew his or her license while it was under suspension, or who has been a manager, administrator, owner, member, officer, director, associate, partner, or any other person with management or control of any partnership, corporation, trust, firm, or association whose application for a license has been denied or revoked, is under suspension or has been placed on probation, and while acting as the manager, administrator, owner, member, officer, director, associate, partner, or any other person with management or control had knowledge of or knowingly participated in any conduct for which the license was denied, revoked, suspended, or placed on probation, shall be prohibited from serving as a manager, administrator, owner, member, officer, director, associate, partner, or in any other position with management or control of a licensee as follows:

(1) Where a probationary license is issued or where an existing license is placed on probation, this prohibition shall remain in effect for a period not to exceed five years.

(2) Where the license is denied or revoked, the prohibition shall continue until the license is issued or reinstated.

(b) “Manager, administrator, owner, member, officer, director, associate, partner, or any other person with management or control of a license” as used in this section and Section 4308, may refer to a pharmacist or to any other person who serves in such capacity in or for a licensee.

76. Pursuant to Code section 4307, if discipline is imposed on Pharmacy Permit Number PHY 55733 issued to Glove Work, Inc., dba Corbin Pharmacy, then Glove Work, Inc., dba Corbin Pharmacy shall be prohibited from serving as a manager, administrator, owner, member, officer, director, associate, or partner of a licensee for five years if Pharmacy Permit Number PHY 55733 is placed on probation or until Pharmacy Permit Number PHY 55733 is revoked.

77. Pursuant to Code section 4307, if discipline is imposed on Pharmacy Permit Number PHY 55733 issued to Glove Work, Inc., dba Corbin Pharmacy, if Respondent Katz had knowledge of or knowingly participated in any conduct for which the licensee was disciplined, then Respondent Katz shall be prohibited from serving as a manager, administrator, owner, member, officer, director, associate, or partner of a licensee for five years if Pharmacy Permit Number PHY 55733 is placed on probation or until Pharmacy Permit Number PHY 55733 is reinstated if it is revoked.

78. Pursuant to Code section 4307, if discipline is imposed on Pharmacist License Number RPH 70481 issued to Respondent Jane Hyun Hong, then she shall be prohibited from serving as a manager, administrator, owner, member, officer, director, associate, or partner of a licensee for five years if Pharmacist License Number RPH 70481 is placed on probation or until Pharmacist License Number RPH 70481 is reinstated if it is revoked.

79. Pursuant to Code section 4307, if discipline is imposed on Pharmacist License Number RPH 40805 issued to Respondent Mehrnaz Akhavan, then she shall be prohibited from serving as a manager, administrator, owner, member, officer, director, associate, or partner of a licensee for five years if Pharmacist License Number RPH 40805 is placed on probation or until Pharmacist License Number RPH 40805 is reinstated if it is revoked.

PRAYER

WHEREFORE, Complainant requests that a hearing be held on the matters herein alleged, and that following the hearing, the Board of Pharmacy issue a decision:

- 1 1. Revoking or suspending Pharmacy Permit Number PHY 55733, issued to Glove
2 Work, Inc., dba Corbin Pharmacy;
- 3 2. Revoking or suspending Registered Pharmacist License Number RPH 70481, issued
4 to Jane Hyun Hong;
- 5 3. Revoking or suspending Registered Pharmacist License Number RPH 40805, issued
6 to Mehrnaz Akhavan;
- 7 4. Prohibiting Glove Work, Inc., dba Corbin Pharmacy from serving as a manager,
8 Administrator, owner, member, officer, director, associate, or partner of a licensee for five years
9 if Pharmacy Permit Number PHY 55733 is placed on probation or until Pharmacy Permit Number
10 PHY 55733 is reinstated if Pharmacy Permit Number PHY 55733 issued to Glove Work, Inc.,
11 dba Corbin Pharmacy is revoked;
- 12 5. Prohibiting Scott Katz from serving as a manager, administrator, owner,
13 member, officer, director, associate, or partner of a licensee for five years if Pharmacy Permit
14 Number PHY 55733 is placed on probation or until Pharmacy Permit Number PHY 55733 is
15 reinstated if Pharmacy Permit Number PHY 55733 issued to Glove Work, Inc., dba Corbin
16 Pharmacy is revoked;
- 17 6. Prohibiting Jane Hyun Hong from serving as a manager, administrator, owner,
18 member, officer, director, associate, or partner of a licensee for five years if Pharmacist License
19 Number RPH 70481 is placed on probation or until Pharmacist License Number RPH 70481 is
20 reinstated if it is revoked.
- 21 7. Prohibiting Mehrnaz Akhavan from serving as a manager, administrator,
22 owner, member, officer, director, associate, or partner of a licensee for five years if Pharmacist
23 License Number RPH 40805 is placed on probation or until Pharmacist License Number RPH
24 40805 is reinstated if it is revoked.
- 25 8. Ordering Glove Work, Inc., dba Corbin Pharmacy, Scott Katz, Jane Hyun Hong and
26 Mehrnaz Akhavan to pay the Board of Pharmacy the reasonable costs of the investigation and
27 enforcement of this case, pursuant to Business and Professions Code section 125.3; and,
28 ///

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

9. Taking such other and further action as deemed necessary and proper.

DATED: 2/24/2023

Sodergren,
Anne@DCA

Digitally signed by Sodergren,
Anne@DCA
Date: 2023.02.24 13:33:04 -08'00'

ANNE SODERGREN
Executive Officer
Board of Pharmacy
Department of Consumer Affairs
State of California
Complainant

LA2020604104
65707451.docx